End-of-life matters in chronic heart failure patients

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 4, 2014, Pages 364-370

  Sobanski, Piotr ^a,b   Jaarsma, Tiny ^c   Krajnik, Malgorzata ^d  

^a Hildegard Palliative Centre   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c LINKÖPING UNIVERSITY   (Sweden)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Death and dying; End of life; Heart failure; Implanted cardiac devices

Indexed keywords

AGE; AGED; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERPERSONAL COMMUNICATION; KAPLAN MEIER METHOD; MALE; PATHOPHYSIOLOGY; SEX DIFFERENCE; TERMINAL CARE;

AGE FACTORS; AGED; COMMUNICATION; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PHYSIOPATHOLOGY; SEX FACTORS; TERMINAL CARE;

EID: 84928152266     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000094     Document Type: Review

References (28)

1. Martinez-Selles M, Doughty RN, Poppe K, et al. Gender and survival in patients with heart failure: Interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail 2012; 14:473-479.
2. Chang PP, hambless LE, Shahar E, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2014; 113:504-510.
3. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart 2013; 99:1158-1165.
4. Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: A population study of 5.1 million people. Circulation 2009; 119:515-523.
5. Long E, Swain G, Mangi A. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circulation Heart failure 2014; 7:470-478.
6. Thijssen J, van Rees JB, Venlet J, et al. The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice. Heart Rhythm 2012; 9:1605-1612.
7. Cubbon RM, Gale CP, Kearney LC, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: A study across therapeutic eras. Circ Heart Fail 2011; 4:396-403.
8. Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010; 121:1393-1405.
9. Rickenbacher P, PfistererM, Burkard T, et al. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 2012; 14:1218-1229.
10. Rutten FH, Heddema WS, Daggelders GJ, et al. Primary care patients with heart failure in the last year of their life. Fam Pract 2012; 29:36-42.
11. O'Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159:841.e1-849.e1.
12. Hamaguchi S, Kinugawa S, Sobirin MA, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 2012; 76:1662-1669.
13. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009; 53:334-342.
14. Kheirbek R, Alemi F, Citron B, et al. Trajectory of illness for patients with congestive heart failure. J Palliat Med 2013; 16:478-484.
15. Janssen DJ, Spruit MA, Schols JM, et al. A call for high-quality advance care planning in outpatients with severe COPD or chronic heart failure. Chest 2011; 139:1081-1088.
16. Dunlay SM, Swetz KM, Mueller PS, et al. Advance directives in community patients with heart failure. Circ Cardiovasc Qual Outcomes 2012; 5:283-289.
17. Matlock DD, Stevenson LW. Life-saving devices reach the end of life with heart failure. Prog Cardiovasc Dis 2012; 55:274-281.
18. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail 2010; 16:106-113.
19. Dunlay SM, Roger VL. Living and dying with heart failure: It's time to talk. Eur Heart J 2012; 33:689-691.
20. Barclay S, Momen N, Case-Upton S, et al. End-of-life care conversations with heart failure patients: A systematic literature review and narrative synthesis. Br J Gen Pract 2011; 61:e49-e62.
21. Brunner-La Rocca HP, Rickenbacher P, Muzzarelli S, et al. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 2012; 33:752-759.
22. Matlock DD, Allen LA. Defibrillators, deactivation, decisions, and dying. JAMA Intern Med 2013; 173:375-394.
23. Reith S, Janssens U. [Dying with/despite a pacemaker]. Med Klin Intensivmed Notfmed 2014; 109:19-26.
24. Dodson JA, Fried TR, Van Ness PH, et al. Patient preferences for deactivation of implantable cardioverter-defibrillators. JAMA Intern Med 2013; 173:377- 379.
25. Herman D, Stros P, Curila K, et al. Deactivation of implantable cardioverterdefibrillators: results of patient surveys. Europace 2013; 15:963- 969.
26. Kraynik SE, Casarett DJ, Corcoran AM. Implantable cardioverter defibrillator deactivation: A hospice quality improvement initiative. J Pain Symptom Manage 2014; 48:471-477.
27. Ben Gal T, Jaarsma T. Self-care and communication issues at the end of life of recipients of a left-ventricular assist device as destination therapy. Curr Opin Support Palliat Care 2013; 7:29-35.
28. Rady MY, Verheijde JL. Ethical challenges with deactivation of durable mechanical circulatory support at the end of life: left ventricular assist devices and total artificial hearts. J Intensive Care Med 2014; 29:3-12.